PPARA and metabolic dysfunction-associated steatotic liver disease: Although there have been advances in lipid-lowering therapy including peroxisome proliferation activating receptors (PPAR)-α/γ agonists and statins, NAFLD still afflicted 1.7 billion population worldwide [5–7].